ThinkGenetic announces that Chief Genetic Officer, Dawn Laney, MS, CGC, CCRC, will be participating in a 19th Annual WORLDSymposium™ Satellite Symposia entitled “Understanding Phenotypic Variability in Lysosomal Diseases – Gaining a Foothold in Precision Medicine” sponsored by Takeda Pharmaceutical Company Limited. The WORLDSymposium™ is an annual research conference dedicated to lysosomal diseases and will be taking place in Orlando, Florida February 22 – 26, 2023.
This symposium is designed for basic, translational, and clinical researchers, patient advocacy groups, clinicians, and all others who are interested in learning more about the latest discoveries related to lysosomal diseases and the clinical investigation of these advances. The session will be a LIVE in-person gathering in Orlando at the Hilton Orlando Hotel. In addition, plans are also underway to make the program available ON DEMAND after the conference ends to allow for registration for those who are unable to attend in person.”
Other ThinkGenetic team members in attendance at WORLD will include:
- Cian Robinson – Chief Revenue Officer
- Carol, Ogg, BS Pharm – VP of Business Development
Members of the leadership team continue to participate in this annual event for its important research presentations and to meet with key decision-makers to discuss potential partnership opportunities.
Interested in scheduling a meeting with ThinkGenetic at the WORLDSymposium? Contact us to learn more.
Panel Presentation at Satellite Symposia
Date and Time: Thursday, February 23, 2023, 5:15 PM – 6:15 PM EST
Title: Understanding Phenotypic Variability in Lysosomal Diseases – Gaining a Foothold in Precision Medicine
Panel includes:
- Dawn Laney, MS, CGC, CCRC – Emory University School of Medicine
- Charlotte Hobbs, MD, PhD – Rady Children’s Institute for Genomic Medicine
- Melissa Wasserstein, MD – The Children’s Hospital at Montefiore and the Albert Einstein College of Medicine
Sponsor: Takeda Pharmaceutical Company Limited
About WORLDSymposium
WORLDSymposium™ is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We’re Organizing Research on Lysosomal Diseases. The goal of WORLDSymposium is to provide an interdisciplinary forum to explore and discuss specific areas of interest, research and clinical applicability related to lysosomal diseases. Each year, WORLDSymposium hosts a scientific meeting presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases. This symposium is designed to help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases, identify areas requiring additional basic and clinical research, public policy and regulatory attention, and identify the latest findings in the natural history of lysosomal diseases.
About ThinkGenetic, Inc.
ThinkGenetic is digitally revolutionizing undiagnosed patient identification with the goal of shortening the diagnostic journey for those with an underlying genetic condition. Harnessing the power of electronic health data and validated proprietary algorithms, our solutions precisely identify at-risk patients and provide resources to support critical healthcare decisions. For more information, visit thinkgenetic.com.
About Dawn Laney, MS, CGC, CCRC
Dawn is a leader in the fields of genetics and education as well as a certified genetic counselor with over 20 years of experience. In 2016, she was formally recognized as a leader in the field of rare genetic diseases by the National Organization for Rare Disorders. Dawn’s academic roles include Assistant Professor of Human Genetics, Director of the Genetic Clinical Trials Center, and Program Leader of the Lysosomal Storage Disease Center (LSDC) Program at Emory University School of Medicine. As a founder and Chief Genetic Officer of ThinkGenetic, Dawn is instrumental in designing and developing the rich, informative content that ThinkGenetic uses as our knowledge base.
[2023-02-08] The Takeda team has approved the release of this communication.
Join the Conversation